FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091246702> ?p ?o ?g. }

• W2091246702 endingPage "1501" @default.
• W2091246702 startingPage "1493" @default.
• W2091246702 abstract "OBJECTIVE To quantify the adherence of patients to drug therapy for osteoporosis in real-world settings via a systematic review and meta-analysis of observational studies. METHODS The PubMed and Cochrane databases were searched for English-language observational studies published from January 1, 1990, to February 15, 2006, that assessed patient adherence to drug therapy for osteoporosis using the following medical subject headings and keywords: drug therapy, medication adherence, medication persistence, medication possession ratio, patient compliance, and osteoporosis. Studies were stratified into 3 groups: persistence (how long a patient continues therapy), compliance (how correctly, in terms of dose and frequency, a patient takes the medication), and adherence (a combination of persistence and compliance). A random-effects model was used to pool results from the selected studies. RESULTS Twenty-four studies were included in the meta-analysis. The pooled database-derived persistence rate was 52% (95% confidence interval [CI], 44%-59%) for treatment lasting 1 to 6 months, 50% (95% CI, 37%-63%) for treatment lasting 7 to 12 months, 42% (95% CI, 20%-68%) for treatment lasting 13 to 24 months, returning to 52% (95% CI, 45%-58%) for treatment lasting more than 24 months. Pooled adherence rates decreased from 53% (95% CI, 52%-54%) for treatment lasting 1 to 6 months to 43% for treatment lasting 7 to 12 months (95% CI, 38%-49%) or 13 to 24 months (43%; 95% CI, 32%-54%). The pooled refill compliance estimate was 68% (95% CI, 63%-72%) for treatment lasting 7 to 12 months and 68% (95% CI, 67%-69%) for treatment lasting 13 to 24 months. The pooled self-reported compliance rate was 62% (95% CI, 48%-75%) for treatment lasting 1 to 6 months and 66% (95% CI, 45%-81%) for treatment lasting 7 to 12 months. CONCLUSION One-third to half of patients do not take their medication as directed. Nonadherence occurs shortly after treatment initiation. Terms and definitions need to be standardized to permit comparability of technologies designed to improve patient adherence. Prospective trials are needed to assess the relationship between adherence and patient outcomes. To quantify the adherence of patients to drug therapy for osteoporosis in real-world settings via a systematic review and meta-analysis of observational studies. The PubMed and Cochrane databases were searched for English-language observational studies published from January 1, 1990, to February 15, 2006, that assessed patient adherence to drug therapy for osteoporosis using the following medical subject headings and keywords: drug therapy, medication adherence, medication persistence, medication possession ratio, patient compliance, and osteoporosis. Studies were stratified into 3 groups: persistence (how long a patient continues therapy), compliance (how correctly, in terms of dose and frequency, a patient takes the medication), and adherence (a combination of persistence and compliance). A random-effects model was used to pool results from the selected studies. Twenty-four studies were included in the meta-analysis. The pooled database-derived persistence rate was 52% (95% confidence interval [CI], 44%-59%) for treatment lasting 1 to 6 months, 50% (95% CI, 37%-63%) for treatment lasting 7 to 12 months, 42% (95% CI, 20%-68%) for treatment lasting 13 to 24 months, returning to 52% (95% CI, 45%-58%) for treatment lasting more than 24 months. Pooled adherence rates decreased from 53% (95% CI, 52%-54%) for treatment lasting 1 to 6 months to 43% for treatment lasting 7 to 12 months (95% CI, 38%-49%) or 13 to 24 months (43%; 95% CI, 32%-54%). The pooled refill compliance estimate was 68% (95% CI, 63%-72%) for treatment lasting 7 to 12 months and 68% (95% CI, 67%-69%) for treatment lasting 13 to 24 months. The pooled self-reported compliance rate was 62% (95% CI, 48%-75%) for treatment lasting 1 to 6 months and 66% (95% CI, 45%-81%) for treatment lasting 7 to 12 months. One-third to half of patients do not take their medication as directed. Nonadherence occurs shortly after treatment initiation. Terms and definitions need to be standardized to permit comparability of technologies designed to improve patient adherence. Prospective trials are needed to assess the relationship between adherence and patient outcomes." @default.
• W2091246702 created "2016-06-24" @default.
• W2091246702 creator A5003308463 @default.
• W2091246702 creator A5004479985 @default.
• W2091246702 creator A5015274357 @default.
• W2091246702 creator A5019902522 @default.
• W2091246702 creator A5044822280 @default.
• W2091246702 date "2007-12-01" @default.
• W2091246702 modified "2023-10-10" @default.
• W2091246702 title "Systematic Review and Meta-analysis of Real-World Adherence to Drug Therapy for Osteoporosis" @default.
• W2091246702 cites W1492812147 @default.
• W2091246702 cites W1976118945 @default.
• W2091246702 cites W1984597244 @default.
• W2091246702 cites W1985327136 @default.
• W2091246702 cites W1997258883 @default.
• W2091246702 cites W1998033364 @default.
• W2091246702 cites W1998243998 @default.
• W2091246702 cites W2001617346 @default.
• W2091246702 cites W2007233990 @default.
• W2091246702 cites W2010816405 @default.
• W2091246702 cites W2011658516 @default.
• W2091246702 cites W2013558878 @default.
• W2091246702 cites W2013724724 @default.
• W2091246702 cites W2021042232 @default.
• W2091246702 cites W2028896946 @default.
• W2091246702 cites W2029141305 @default.
• W2091246702 cites W2029487646 @default.
• W2091246702 cites W2039860789 @default.
• W2091246702 cites W2043018151 @default.
• W2091246702 cites W2048541373 @default.
• W2091246702 cites W2052991251 @default.
• W2091246702 cites W2057112394 @default.
• W2091246702 cites W2060242325 @default.
• W2091246702 cites W2060739264 @default.
• W2091246702 cites W2063780338 @default.
• W2091246702 cites W2065667486 @default.
• W2091246702 cites W2070531118 @default.
• W2091246702 cites W2074724534 @default.
• W2091246702 cites W2089100007 @default.
• W2091246702 cites W2091930575 @default.
• W2091246702 cites W2104922575 @default.
• W2091246702 cites W2107544704 @default.
• W2091246702 cites W2108526974 @default.
• W2091246702 cites W2110199574 @default.
• W2091246702 cites W2116831044 @default.
• W2091246702 cites W2129577780 @default.
• W2091246702 cites W2131056136 @default.
• W2091246702 cites W2145355470 @default.
• W2091246702 cites W2151512706 @default.
• W2091246702 cites W2155441883 @default.
• W2091246702 cites W2156171368 @default.
• W2091246702 cites W2158787920 @default.
• W2091246702 cites W2158943274 @default.
• W2091246702 cites W2162647625 @default.
• W2091246702 cites W2166982858 @default.
• W2091246702 cites W2167281689 @default.
• W2091246702 cites W2167515284 @default.
• W2091246702 cites W75159450 @default.
• W2091246702 doi "https://doi.org/10.1016/s0025-6196(11)61093-8" @default.
• W2091246702 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18053457" @default.
• W2091246702 hasPublicationYear "2007" @default.
• W2091246702 type Work @default.
• W2091246702 sameAs 2091246702 @default.
• W2091246702 citedByCount "240" @default.
• W2091246702 countsByYear W20912467022012 @default.
• W2091246702 countsByYear W20912467022013 @default.
• W2091246702 countsByYear W20912467022014 @default.
• W2091246702 countsByYear W20912467022015 @default.
• W2091246702 countsByYear W20912467022016 @default.
• W2091246702 countsByYear W20912467022017 @default.
• W2091246702 countsByYear W20912467022018 @default.
• W2091246702 countsByYear W20912467022019 @default.
• W2091246702 countsByYear W20912467022020 @default.
• W2091246702 countsByYear W20912467022021 @default.
• W2091246702 countsByYear W20912467022022 @default.
• W2091246702 countsByYear W20912467022023 @default.
• W2091246702 crossrefType "journal-article" @default.
• W2091246702 hasAuthorship W2091246702A5003308463 @default.
• W2091246702 hasAuthorship W2091246702A5004479985 @default.
• W2091246702 hasAuthorship W2091246702A5015274357 @default.
• W2091246702 hasAuthorship W2091246702A5019902522 @default.
• W2091246702 hasAuthorship W2091246702A5044822280 @default.
• W2091246702 hasConcept C126322002 @default.
• W2091246702 hasConcept C23131810 @default.
• W2091246702 hasConcept C2776541429 @default.
• W2091246702 hasConcept C2776999253 @default.
• W2091246702 hasConcept C44249647 @default.
• W2091246702 hasConcept C71924100 @default.
• W2091246702 hasConcept C95190672 @default.
• W2091246702 hasConceptScore W2091246702C126322002 @default.
• W2091246702 hasConceptScore W2091246702C23131810 @default.
• W2091246702 hasConceptScore W2091246702C2776541429 @default.
• W2091246702 hasConceptScore W2091246702C2776999253 @default.
• W2091246702 hasConceptScore W2091246702C44249647 @default.
• W2091246702 hasConceptScore W2091246702C71924100 @default.
• W2091246702 hasConceptScore W2091246702C95190672 @default.
• W2091246702 hasIssue "12" @default.
• W2091246702 hasLocation W20912467021 @default.

• next